Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b MAD Study of EC5026 in Healthy Volunteers
NCT06089837Phase 1Completed
- Sponsor
- EicOsis Human Health
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain and neuropathic pain comparing EC5026 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) at 30 days, Dose-related effects on electrocardiographic QTc interval at 7 days and 11 more. Started Nov 2023; status: completed.
02
Drugs
EC5026
03
Conditions
painneuropathic pain
Beyond the preview
Go deeper on NCT06089837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089837.